TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29
2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.6 MULTIVARIATE MODELLING 36
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
2.8 DBMR MARKET POSITION GRID 37
2.9 VENDOR SHARE ANALYSIS 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 SECONDARY SOURCES 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTEL ANALYSIS 45
4.2 PORTERS FIVE FORCES 46
5 EPIDEMIOLOGY 47
6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48
7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49
7.1 REGULATORY SCENARIO IN THE U.S 49
7.2 REGULATORY SCENARIO IN AUSTRALIA 50
7.3 REGULATORY SCENARIO IN JAPAN 50
7.4 REGULATORY SCENARIO IN CHINA 50
8 MARKET OVERVIEW 52
8.1 DRIVERS 54
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
8.1.3 IMPROVED IMAGING TECHNIQUES 55
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
8.2 RESTRAINTS 56
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
8.3 OPPORTUNITIES 57
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
8.3.3 RISING HEALTHCARE EXPENDITURE 58
8.4 CHALLENGES 59
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59
9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60
9.1 OVERVIEW 61
9.2 IMAGING TEST 64
9.2.1 CT SCAN 65
9.2.2 MRI 65
9.2.3 PET 65
9.2.4 OTHERS 65
9.3 MOLECULAR TESTING 66
9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
9.5 LUMBAR PUNCTURE 67
9.6 BIOPSY 68
9.6.1 OPEN BIOPSY 69
9.6.2 STEREOTACTIC BIOPSY 69
9.6.3 NEEDLE BIOPSY 69
9.6.4 NEUROENDOSCOPY 69
9.7 OTHERS 69
10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70
10.1 OVERVIEW 71
10.2 GLIOBLASTOMA MULTIFORME 74
10.3 MENINGIOMAS 75
10.4 ASTROCYTOMAS 76
10.5 ACOUSTIC NEUROMA 77
10.6 OLIGODENDROGLIOMA 78
10.7 OLIGODENDROGLIOMA 78
10.8 OTHERS 79
11 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80
11.1 OVERVIEW 81
11.2 35-65 84
11.3 65 AND ABOVE 85
11.4 BELOW 21 86
11.5 21-34 87
12 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88
12.1 OVERVIEW 89
12.2 HOSPITALS 92
12.3 SPECIALTY CLINICS 93
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
12.5 AMBULATORY SURGICAL CENTERS 95
12.6 OTHERS 96
13 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97
13.1 EUROPE 98
13.1.1 GERMANY 105
13.1.2 FRANCE 107
13.1.3 U.K. 109
13.1.4 ITALY 111
13.1.5 SPAIN 113
13.1.6 RUSSIA 115
13.1.7 SWITZERLAND 117
13.1.8 NETHERLANDS 119
13.1.9 TURKEY 121
13.1.10 BELGIUM 123
13.1.11 REST OF EUROPE 125
14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 126
14.1 COMPANY SHARE ANALYSIS: EUROPE 126
15 SWOT ANALYSIS 127
16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 128
16.1 KONINKLIJKE PHILIPS N.V. 128
16.1.1 COMPANY SNAPSHOT 128
16.1.2 REVENUE ANALYSIS 128
16.1.3 COMPANY SHARE ANALYSIS 129
16.1.4 PRODUCT PORTFOLIO 129
16.1.5 RECENT DEVELOPMENTS 130
16.2 CANON INC. 131
16.2.1 COMPANY SNAPSHOT 131
16.2.2 REVENUE ANALYSIS 131
16.2.3 COMPANY SHARE ANALYSIS 132
16.2.4 PRODUCT PORTFOLIO 132
16.2.5 RECENT DEVELOPMENT 132
16.3 SIEMENS HEALTHCARE GMBH 133
16.3.1 COMPANY SNAPSHOT 133
16.3.2 REVENUE ANALYSIS 134
16.3.3 COMPANY SHARE ANALYSIS 134
16.3.4 PRODUCT PORTFOLIO 135
16.3.5 RECENT DEVELOPMENTS 135
16.4 BD 136
16.4.1 COMPANY SNAPSHOT 136
16.4.2 REVENUE ANALYSIS 137
16.4.3 COMPANY SHARE ANALYSIS 137
16.4.4 PRODUCT PORTFOLIO 138
16.4.5 RECENT DEVELOPMENTS 138
16.5 NIHON KOHDEN CORPORATION. 139
16.5.1 COMPANY SNAPSHOT 139
16.5.2 RECENT FINANCIALS 139
16.5.3 COMPANY SHARE ANALYSIS 140
16.5.4 PRODUCT PORTFOLIO 140
16.5.5 RECENT DEVELOPMENT 140
16.6 BIOCEPT, INC. 141
16.6.1 COMPANY SNAPSHOT 141
16.6.2 REVENUE ANALYSIS 141
16.6.3 PRODUCT PORTFOLIO 142
16.6.4 RECENT DEVELOPMENT 142
16.7 BIOMIND 143
16.7.1 COMPANY SNAPSHOT 143
16.7.2 PRODUCT PORTFOLIO 143
16.7.3 RECENT DEVELOPMENT 143
16.8 CEREBRAL DIAGNOSTIC 144
16.8.1 COMPANY SNAPSHOT 144
16.8.2 PRODUCT PORTFOLIO 144
16.8.3 RECENT DEVELOPMENT 144
16.9 DXCOVER LIMITED 145
16.9.1 COMPANY SNAPSHOT 145
16.9.2 PRODUCT PORTFOLIO 145
16.9.3 RECENT DEVELOPMENT 145
16.10 FONAR CORP. 146
16.10.1 COMPANY SNAPSHOT 146
16.10.2 REVENUE ANALYSIS 146
16.10.3 PRODUCT PORTFOLIO 147
16.10.4 RECENT DEVELOPMENT 147
16.11 FUJIFILM CORPORATION 148
16.11.1 COMPANY SNAPSHOT 148
16.11.2 REVENUE ANALYSIS 148
16.11.3 PRODUCT PORTFOLIO 149
16.11.4 RECENT DEVELOPMENT 149
16.12 GE HEALTHCARE. 150
16.12.1 COMPANY SNAPSHOT 150
16.12.2 REVENUE ANALYSIS 150
16.12.3 PRODUCT PORTFOLIO 151
16.12.4 RECENT DEVELOPMENT 151
16.13 HITACHI, LTD. 152
16.13.1 COMPANY SNAPSHOT 152
16.13.2 REVENUE ANALYSIS 152
16.13.3 PRODUCT PORTFOLIO 153
16.13.4 RECENT DEVELOPMENT 153
16.14 MINFOUND MEDICAL SYSTEMS CO., 154
16.14.1 COMPANY SNAPSHOT 154
16.14.2 PRODUCT PORTFOLIO 154
16.14.3 RECENT DEVELOPMENT 154
16.15 NANTOMICS. 155
16.15.1 COMPANY SNAPSHOT 155
16.15.2 PRODUCT PORTFOLIO 155
16.15.3 RECENT DEVELOPMENT 155
16.16 NEUSOFT CORPORATION 156
16.16.1 COMPANY SNAPSHOT 156
16.16.2 REVENUE ANALYSIS 156
16.16.3 PRODUCT PORTFOLIO 157
16.16.4 RECENT DEVELOPMENT 157
16.17 SEQUOIA HEALTHCARE. 158
16.17.1 COMPANY SNAPSHOT 158
16.17.2 PRODUCT PORTFOLIO 158
16.17.3 RECENT DEVELOPMENT 158
16.18 STERNMED GMBH 159
16.18.1 COMPANY SNAPSHOT 159
16.18.2 PRODUCT PORTFOLIO 159
16.18.3 RECENT DEVELOPMENT 159
16.19 THERMO FISHER SCIENTIFIC INC. 160
16.19.1 COMPANY SNAPSHOT 160
16.19.2 REVENUE ANALYSIS 160
16.19.3 PRODUCT PORTFOLIO 161
16.19.4 RECENT DEVELOPMENT 161
16.20 TIME MEDICAL HOLDING. 162
16.20.1 COMPANY SNAPSHOT 162
16.20.2 PRODUCT PORTFOLIO 162
16.20.3 RECENT DEVELOPMENTS 162
17 QUESTIONNAIRE 163
18 RELATED REPORTS 166

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.